Faron Pharmaceuticals Oy (FRA:4FR)

Full Year 2025 Faron Pharmaceuticals Oy Earnings Call Transcript

Mar 4, 2026 / 02:00 PM GMT

Release Date Price: €0.548259 (-0.17%)

Transcript

Key Points

Positve

Faron Pharmaceuticals Oy (FRA:4FR) achieved outstanding clinical results in treating high-risk myelodysplastic syndromes (MDS), with deep and durable complete remissions and transfusion independence.
The company successfully completed a phase 2 meeting with the FDA, setting the stage for a phase 2/3 trial in the frontline setting.
Faron Pharmaceuticals Oy maintained a solid cash position, even repaying its IPF debt facility in a challenging equity market.
The company strengthened its management team, including the appointment of a new CFO and other key board members.
There is significant interest among physicians to investigate the company's drug, Bex, in various indications, leading to cost-efficient investigator-initiated trials.

Negative

Faron Pharmaceuticals Oy ended the year with a loss of EUR 27.3 million, highlighting ongoing financial challenges.
The company plans to raise EUR 40 million to fund its phase 2B trial, indicating a need for substantial additional capital.
Despite positive results, the company faces competition and the need to differentiate its drug from others in the market.
The company is still in the early stages of its phase 2/3 trial, with significant work needed to reach phase 3 and eventual approval.
There are ongoing risks associated with the development of new drugs, including potential adverse events and regulatory hurdles.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

FARN.L - Faron Pharmaceuticals Oy
Full Year 2025 Faron Pharmaceuticals Oy Earnings Call
Mar 04, 2026 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello everyone. Welcome to the Fron Pharmaceuticals annual results webcast for 2025. My name is Yoi Alkanen, the CEO of the company. Here with me today, our new CFO Yuran.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Hi, my name is Julian Deckers. I started as CFO on the 1st of December 2025, replacing Ero, who decided to retire by the end of March this year.

When working in different global, regional and local finance roles over the last 25 years with a focus on healthcare and biotech.

My last role was at Broyard Therapeutics, CFO of a Dutch

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.